Loading
companiesCompany
Argos Therapeutics
Argos was a North Carolina company whose personalised dendritic-cell vaccine rocapuldencel-T, made from each patient's own tumour RNA, failed the phase 3 ADAPT trial in kidney cancer and the company closed in 2019.
Also called: Argos Therapeutics, Inc.Argos
Overview
Argos Therapeutics, founded in 1997 in Durham, North Carolina, built the Arcelis platform, which loaded a patient's dendritic cells with RNA amplified from their own tumour. Rocapuldencel-T (AGS-003) was tested with sunitinib in the phase 3 ADAPT trial in metastatic renal cell carcinoma; the trial was stopped for futility in 2017 and the company filed for bankruptcy in 2019. Its trials remain on ClinicalTrials.gov under Argos as lead sponsor.
Headquarters
Durham, NC, US
Type
Stage
Wound down
Website
Founded
1997
Similar pages
- CompanyMedigene
Shares Dendritic cell vaccines, Pivotal (registrational) trial, Clinical trial.
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals